Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02312557
Title Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute

prostate cancer


Enzalutamide + Pembrolizumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.